Effectiveness, tolerability and acceptance of an oral estradiol/levonorgestrel formulation for the treatment of menopausal complaints: a non-interventional observational study over six cycles of 28 days

References

• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;CD004143
   PubMedGoogle Scholar
• The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• Ortmann O, Dören M, Windler E. Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstetr 2011;284:343–55
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Gass LS, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203–4
   PubMed Web of Science ®Google Scholar
• Moyer VA on behalf of the U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013;158:47–54
   Google Scholar
• Valdiviezo C, Lawson S, Ouyang P. An update on menopausal hormone replacement therapy in women and cardiovascular disease. Curr Opin Endocrinol Diabet Obes 2013;20:148–55
   PubMedGoogle Scholar
• Davies E, Mangongi NP, Carter CL. Is timing everything?. A meeting report of the Society for Women's Health Research Roundtable on Menopausal Hormone Therapy. J Women's Health 2013;22:303–11
   PubMed Web of Science ®Google Scholar
• Medicinal Products Act in the version published on 12 December 2005 (Federal Law Gazette [BGBl.]) Part I p. 3394, last amended by Article 1 of the Law of 19th October 2012 (Federal Law Gazette I p. 2192). Available from: http://www.gesetze-im-internet.de/englisch_amg/englisch_amg.html#p0073 [Last accessed 28 May 2014]
   Google Scholar
• Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen [Recommendations of the Federal Institute for Drugs and Medical Devices and the Paul-Ehrlich-Institute (Germany) for the Planning, Accomplishment and Evaluation of Observational Studies]: Available from: http://www.pei.de/SharedDocs/Downloads/pu/klinische-pruefung/100707-awb-kommentierung-fachkreise.pdf;jsessionid=0CE9C17C31690914A9CC0EE49BDFE7F4.1_cid344?__blob=publicationFile&v=1 [Last accessed 28 May 2014]
   Google Scholar
• Summary of Product Characteristics: Wellnara® 1 mg/ 0.4 mg Filmtablette. January 2012 Available from: http://www.fachinfo.de/#suche/fi/014471 [Last accessed 04 Jun 2014]
   Google Scholar
• Heinemann LAJ, DoMinh T, Strelow F, et al. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcom 2004;2:67
   PubMedGoogle Scholar
• Kakkar V, Kaur D, Chopra K, et al. Assessment of the variation in menopausal symptoms with age, education and working/non-working status in north-Indian sub-population using menopause rating scale (MRS). Maturitas 2007;57:306–14
   PubMed Web of Science ®Google Scholar
• Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589–601
   PubMed Web of Science ®Google Scholar
• Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 2011;8:669–76
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens – a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865–83
   PubMed Web of Science ®Google Scholar
• Curran MP, Wagstaff AJ. Estradiol and norgestimate - a review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging 2001;18:863–85
   PubMed Web of Science ®Google Scholar
• Rowan JP, Simon JA, Speroff L, Ellman H. Effects of low-dose norethinendrone acetate plus ethinyl estradiol (0.5 mg/2.5 mcg) in women with menopausal symptoms: updated analysis of three randomized controlled trials. Clin Therapeut 2006;28:921–32
   PubMed Web of Science ®Google Scholar
• Speroff L, Symons J, Kempfert N, Rowan J (for the FemHRT Study Investigators). The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femHRT®) on the frequency and intensity of vasomotor symptoms. Menopause 2000;7:383–90
   PubMed Web of Science ®Google Scholar
• Baerug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1:219–28
   PubMedGoogle Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al.; Women's Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstetr Gynecol 2005;105:1063–73
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Spielmann D, Genazzani AR. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate. Gynecol Endocrinol 2005;21:65–73
   PubMed Web of Science ®Google Scholar
• Bouchard P, De Cicco-Nardone F, Spielman D, Garcea N, Trimegestone 301 Study Group. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol 2005;21:142–48
   PubMed Web of Science ®Google Scholar
• Gräser T, Römer T, Wiedey KD, Janaud A. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001;4:332–42
   PubMedGoogle Scholar
• Foster RH, Balfour JA. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging 1997;11:309–32
   PubMed Web of Science ®Google Scholar
• Althoff B. An open multicenter study to investigate the effect of a continuous oral combination of 1 mg 17ß estradiol and 40 µg levonorgestrel over 13 28-day cycles on the endometrium, bleeding patterns, menopausal symptoms, bone metabolism, and coagulation function in 170 postmenopausal women; 2001; Asche AG internal clinical study report No. A00403
   Google Scholar
• Althoff B. An open multicenter study to investigate the effect of a continuous oral combination of 1 mg 17ß estradiol and 40 µg levonorgestrel over 13 28-day cycles on the endometrium, bleeding patterns, menopausal symptoms, bone metabolism, and coagulation function in 170 postmenopausal women. 2002; Asche AG internal clinical study follow-up report No. A06276
   Google Scholar
• Althoff B. An open randomized, parallel-group multicenter study to investigate the effect of a continuous oral combination of 1 mg 17ß estradiol and 40 µg levonorgestrel vs. 0.625 mg conjugated equine estrogens and 2.5 mg MPA (medroxyprogesterone acetate) over 13 28-day cycles on the endometrium, menopausal symptoms, and bleeding pattern in 390 postmenopausal women. 2001; Asche AG internal clinical study report No. A00404
   Google Scholar
• Phillips TJ, Symons J, Menon S, HT Sudy Group. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. J Am Acad Dermatol 2008;59:397–404
   PubMed Web of Science ®Google Scholar
• Kovalevsky G, Ballagh SA, Stanczyk FZ, et al. Levonorgestrel effects on serum androgens, sex hormone-binding globulin levels, hair shaft diameter, and sexual function. Fertil Steril 2010;93:1997–2003
   PubMed Web of Science ®Google Scholar